Connecting the dots
2021 trends in global clinical trial execution
This month’s PharmaTimes is packed with a variety of features centred on clinical research, the lifeblood of our industry. Our insightful front cover article delves into the key regulatory considerations on both sides of the Atlantic for starting cell and gene therapy trials (p26), while others look at the rise of genetic sequencing (p30) and 2021 trends in global trials (p20).
We also take a look at some promising new therapy areas, with two articles on medical cannabis, focusing on how big pharma can help improve the UK’s market (p38) and the need for a harmonised regulatory framework across Europe (p40), and also breaking new boundaries with virtual therapies (p34) that are showing value for a number of health conditions, including PTSD and pain.
Young leaders take the stage for our monthly Q&A stream of interviews (p13), showcasing promising young stars of healthcare communications, their professional successes and hopes for the future.
Finally, just a reminder that the 2021 PharmaTimes Marketer of the Year, Communications Awards, Sales Awards and Clinical Researcher of the Year – The Americas are all open for entry, while tickets are now on sale for the International Clinical Researcher of the Year gala dinner. For more information visit www.pharmatimes.com/competitions
I hope you enjoy the issue!
2021 trends in global clinical trial execution
Professor Saad Shakir reflects on the gap in public knowledge about routine drug safety and pharmacovigilance activity
Medical cannabis is experiencing a surge of demand in Europe – but a lack of the usual harmonised regulatory framework and diversity in attitudes to cannabis from country to country could pose a challenge.
Dr Jorg Taubel reflects on 20 years in clinical research in the UK: how has it changed and what does this mean for the future?
Environmental risk, biosafety and other key regulatory considerations for cell and gene therapy trials
Anthony Yanni, senior vice president and head of Patient Centricity at Astellas, says that for patient centricity to truly work, it must deliver value to both patients and the business
COVID-19 and the rapid rise of genetic sequencing
With technology evolving at breakneck speed, it’s fair to say that the sky is the limit when it comes to the use of virtual therapeutics
How virtual and augmented reality technologies will support data insights in future
The reality of prescribing freedoms in the UK
RNA treatments and vaccines have just shown the scale of their potential. Now’s the time to position the UK as a global leader
With the pandemic and structural reforms taking their toll on the NHS workforce, Oli Hudson looks at how pharma can develop a sensitive and intelligent engagement approach that reflects the climate of change and uncertainty faced by clinical teams
Should pharma companies consider protecting the shape of their products?
MAGAZINE EXCLUSIVEWinners of the 2021 Best of Business Intelligence (BOBI) awards
Robyn Wagner, Havas Lynx, Group Account Director
Lucy Goodwill, Four Health, Account Manager
Rebecca Godfrey, Four Health, Account Director
James Addicott, Four Health, Senior Account Director
Nicole Corteen, Langland, Principal Medical Writer
Lydia Oikonomidis, Langland, Scientific Strategist